Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 17;39:101723. doi: 10.1016/j.rmcr.2022.101723

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 2 — Chest CT imaging during the clinical course.

Non-enhanced chest CT revealed high attenuation of the mucoid impaction in the left-lingular lobe on referral (March 2019: CT #1) (a, b). Mucoid impaction in the left-lingular lobe has spread 2 months after referral (May 2019: CT #2) (c). Mucoid impaction in the left-lingular lobe has disappeared 2 months after treatment predonisolone (July 2019: CT #3) (d). Mucoid impaction newly occluded in the left-upper lobe on recurrence of ABPA (September 2021: CT #4) (e). The improvement of mucoid impaction in the left-upper lobe is poor and newly mucoid impactions can be seen in the right-upper lobe, right-lower lobe, and left-upper lobe 3 months after treatment with mepolizumab (November 2021: CT #5) (f, g,and h). All mucoid impactions have disappeared 3 months after treatment with dupilumab (Feburuary 2022: CT #6) (i, j, and k).